FcRn Inhibitors Pipeline Review
Target: Neonatal Fc receptor; FcRn
Product Category: Antibody; Small Molecule
This product provides basic information on approved products and R&D candidates targeting FcRn.
This product consists of:
- Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage.
- Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
- One-month online access to La Merie Publishing’s database for approved products and R&D candidates targeting FcRn (prerequisite: access to internet).
This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.
Severe autoimmune diseases can be associated with high levels of pathogenic immunoglobulin G, or IgG, antibodies for which few innovative biologic treatments have been approved and severe unmet medical need exists. A number of monoclonal antibodies have been created to block the interaction of FcRn and Immunoglobulin G (IgG), accelerating the catabolism of antibodies and reducing the concentration of pathogenic IgG autoantibodies. Such treatments have potential in many large and orphan indications, such as multiple sclerosis, immune thrombocytopenia, systemic lupus erythematosus, myasthenia gravis and pemphigus vulgaris.